Short answer
Adicet Bio Inc (ACET) filed its Q2 2019 10-Q quarterly report on Aug 14, 2019 for the quarter ended Jun 30, 2019.
Adicet Bio Inc Q2 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY, with no product sales
- Net loss $18.3M vs $13.6M YoY, operating expenses $19.2M vs $14.1M
- Research and development highest expense: $16.6M vs $11.8M YoY
- Cash and investments $132.8M at June 30, 2019, operating cash outflow $26.4M
- Outlook: funding expected through 2020, additional financing required; Phase 3 data expected in early 2020 and mid-2020
Risk Factors
- No material changes to 2018 Form 10-K risk factors
- Clinical development risk, forward-looking assumptions lack management control
- Regulatory risk, future circumstances subject to uncertainties
- Operational risk, dependence on assumptions regarding clinical development
- Financial risk, carried-forward 2018 Form 10-K risks not detailed in filing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Adicet Bio Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.